Response rates to direct antiviral agents among hepatitis C virus infected patients who develop hepatocellular carcinoma following direct antiviral agents treatment

Abstract

Aim: Patients with chronic hepatitis C virus (HCV) infection who develop hepatocellular carcinoma (HCC) soon after treatment with direct antiviral agents (DAA) may have been harboring hitherto hidden tumors. If this were true, they should have a lower sustained viral response (SVR) rate, since active HCC hampers DAA efficacy. We aimed to verify this hypothesis.

Methods: We included all patients who attended an HCV clinic, provided that they: (1) had no previous history of HCC; (2) had received at least one DAA dose; and (3) had been followed-up clinically and ultrasonographically for at least six months after concluding DAA.

Results: The study population included n = 789 patients (55% males, median age 62 years). A median of 9.3 months (8.8-11.9) after concluding DAA, n = 19 (2.4%) patients were discovered to harbor HCC. In comparison to all others, patients with HCC were more commonly male (84% vs. 54%, P = 0.009), obese (47% vs. 17%, P = 0.002), and cirrhotic (95% vs. 35%, P < 0.001) and had less commonly achieved an SVR (68% vs. 98%, P < 0.001). Moreover, they had a trend for being less commonly treatment naïve (58% vs. 67%, P = 0.051). Based on multivariate analysis, the independent predictors of HCC were male sex (P = 0.031), cirrhosis (P = 0.004), obesity (P = 0.006), and failure to achieve an SVR (P < 0.001).

Conclusion: Lack of achieving SVR is a strong independent predictor of development of HCC early after treatment of hepatitis C with DAA. Treatment failure should further alert clinicians to the possibility of this dreadful complication.

Keywords

Chronic hepatitis C / direct antiviral agent / sustained viral response / hepatocellular carcinoma / obesity / cirrhosis

References

[1] Pawlotsky JM,Aghemo A,Dalgard O.EASL recommendations on treatment of hepatitis C 2018..J Hepatol2018;69:461-511

[2] World Health OrganizationGlobal hepatitis report, 2017.2017;

[3] Reig M,Perelló C,Ribeiro A.Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy..J Hepatol2016;65:719-26

[4] Akinyemiju T,Ahmed M,Alemayho MA.The burden of primary liver cancer and underlying etiologies from 1990 to 2015 at the global, regional, and national level results from the global burden of disease study 2015..JAMA Oncol2017;3:1683-91 PMCID:PMC5824275

[5] Mashiba T,Kurosaki M,Osaki Y.Does interferon-free direct-acting antiviral therapy for hepatitis c after curative treatment for hepatocellular carcinoma lead to unexpected recurrences of hcc? A multicenter study by the Japanese red cross hospital liver study group..PLoS One2018;13:e0194704 PMCID:PMC5901785

[6] Nagata H,Asahina Y,Asano Y.Effect of interferon-based and -free therapy on early occurrence and recurrence of hepatocellular carcinoma in chronic hepatitis C..J Hepatol2017;67:933-9

[7] Virlogeux V,Hartig-Lavie K,Maynard M.Direct-acting antiviral therapy decreases hepatocellular carcinoma recurrence rate in cirrhotic patients with chronic hepatitis C..Liver Int2017;37:1122-7

[8] Su F.Hepatocellular carcinoma risk after direct-acting antiviral therapy..Clin Liver Dis2019;13:6-12 PMCID:PMC6465785

[9] Prenner SB,Flamm SL,Lewandowski RJ.Hepatocellular carcinoma decreases the chance of successful hepatitis C virus therapy with direct-acting antivirals..J Hepatol2017;66:1173-81 PMCID:PMC5776681

[10] European Association for the Study of the LiverEASL recommendations on treatment of hepatitis C 2016..J Hepatol2017;66:153-94

[11] Bedossa P.Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C..Hepatology1994;20:15-20

[12] Castera L,Alberti A.Non-invasive evaluation of liver fibrosis using transient elastography..J Hepatol2008;48:835-47

[13] Galle PR,Llovet JM,Piscaglia F.EASL clinical practice guidelines: management of hepatocellular carcinoma..J Hepatol2018;69:182-236

[14] Mazzaferro V,Doci R,Pulvirenti A.Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis..N Engl J Med1996;334:693-700

[15] Jemal A,Center MM,Ward E.Global cancer statistics..CA Cancer J Clin2011;61:69-90

[16] Liu P,Hu S,Gao T.Age-specific sex difference in the incidence of hepatocellular carcinoma in the United States..Oncotarget2017;8:68131-7 PMCID:PMC5620243

[17] Burlone ME,Giarda P,Pirisi M.Influence of age on sex-related differences among patients with hepatitis C..Eur J Gastroenterol Hepatol2016;28:1100-1

[18] Davis GL,El-Serag H,Jennings LW.Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression..Gastroenterology2010;138:513-21

[19] Nasta P.“Immune activation, aging and gender” and progression of liver disease..Acta Biomed2011;82:115-23

[20] Prieto J.Inflammation, HCC and sex: IL-6 in the centre of the triangle..J Hepatol2008;48:380-1

[21] Cussigh A,Fabris C,Cmet S.Interleukin 6 promoter polymorphisms influence the outcome of chronic hepatitis C..Immunogenetics2011;63:33-41

[22] Fattovich G,Zagni I.Hepatocellular carcinoma in cirrhosis: incidence and risk factors..Gastroenterology2004;127 (5 Suppl 1):S35-50

[23] Simonetti RG,Fiorello F,D’Amico G.Hepatocellular carcinoma - a worldwide problem and the major risk factors..Dig Dis Sci1991;36:962-72

[24] Tsukuma H,Tanaka S,Yabuuchi T.Risk factors for hepatocellular carcinoma among patients with chronic liver disease..N Engl J Med1993;328:1797-1801

[25] Akinyemiju T,Ahmed M,Alemayohu MA.The burden of primary liver cancer and underlying etiologies from 1990 to 2015 at the global, regional, and national level..JAMA Oncol2017;3:1683-91 PMCID:PMC5824275

[26] Degos F,Ganne-Carrie N,Degott C.Hepatitis C virus related cirrhosis: time to occurrence of hepatocellular carcinoma and death..Gut2000;47:131-6 PMCID:PMC1727946

[27] West J,Aithal GP.Risk of hepatocellular carcinoma among individuals with different aetiologies of cirrhosis: a population-based cohort study..Aliment Pharmacol Ther2017;45:983-90

[28] El-Serag HB.Hepatocellular carcinoma..N Engl J Med2011;365:1118-27

[29] Fabris C,Toniutto P,Rapetti R.Assessment of liver fibrosis progression in patients with chronic hepatitis C and normal alanine aminotransferase values: the role of AST to the platelet ratio index..Clin Biochem2006;39:339-43

[30] Alexander J,Wu TT.Non-alcoholic fatty liver disease contributes to hepatocarcinogenesis in non-cirrhotic liver: a clinical and pathological study..J Gastroenterol Hepatol2013;28:848-54

[31] Grohmann M,Dodd GT,Ooi GJ.Obesity drives STAT-1-dependent NASH and STAT-3-dependent HCC..Cell2018;175:1289-306 PMCID:PMC6242467

[32] Burlone ME.Hepatitis C virus cell entry: role of lipoproteins and cellular receptors..J Gen Virol2009;90:1055-70

[33] Schaefer EA.HCV and host lipids: an intimate connection..Semin Liver Dis2013;33:358-68

[34] Kuo YH,Wang JH,Hsiao CC.Association between chronic viral hepatitis and metabolic syndrome in southern Taiwan: a large population-based study..Aliment Pharmacol Ther2018;48:993-1002

[35] Perz JF,Farrington LA,Bell BP.The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide..J Hepatol2006;45:529-38

[36] Yoon H,Yoo JH,Kim DY.Effects of metabolic syndrome on fibrosis in chronic viral hepatitis..Gut Liver2013;7:469-74 PMCID:PMC3724037

[37] Dong TS,Benhammou JN,Han SH.Metabolic syndrome does not affect sustained virologic response of direct-acting antivirals while hepatitis C clearance improves hemoglobin A1c..World J Hepatol2018;10:612-21

[38] Dore GJ,Luo Y,Knysz B.Efficacy and safety of ombitasvir/paritaprevir/r and dasabuvir compared to IFN-containing regimens in genotype 1 HCV patients: the MALACHITE-I/II trials..J Hepatol2016;64:19-28

[39] Zeuzem S,Wang S,Gane E.Glecaprevir-pibrentasvir for 8 or 12 weeks in HCV genotype 1 or 3 infection..N Engl J Med2018;378:354-69

[40] Zeuzem S,Reddy KR,Ari ZB.Grazoprevir-Elbasvir combination therapy for treatment-naive cirrhotic and noncirrhotic patients with chronic hepatitis C virus genotype 1, 4, or 6 infection: a randomized trial..Ann Int Med2015;163:1-13

[41] Buggisch P,Mauss S,Schott E.Real-world effectiveness of 8-week treatment with ledipasvir/sofosbuvir in chronic hepatitis C..J Hepatol2018;68:663-71

[42] Londoño MC,Mallolas J,Ahumada A.Effectiveness, safety/tolerability of OBV/PTV/r ± DSV in patients with HCV genotype 1 or 4 with/without HIV-1 co-infection, chronic kidney disease (CKD) stage IIIb/V and dialysis in Spanish clinical practice - preliminary data Vie-KinD study..J Hepatol2017;66:S718-9

[43] Cardoso H,Rodrigues S,Albuquerque A.High incidence of hepatocellular carcinoma following successful interferon-free antiviral therapy for hepatitis C associated cirrhosis..J Hepatol2016;65:1070-1

[44] Conti F,Scuteri A,Bolondi L.Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals..J Hepatol2016;65:727-33

[45] ANRS collaborative study group on hepatocellular carcinomaLack of evidence of an effect of direct-acting antivirals on the recurrence of hepatocellular carcinoma: data from three ANRS cohorts..J Hepatol2016;65:734-40

[46] Baumert TF,Lim JK.Status of direct-acting antiviral therapy for hepatitis C virus infection and remaining challenges..Gastroenterology2019;156:431-45 PMCID:PMC6446912

[47] Ioannou GN,Berry K.HCV eradication induced by direct-acting antiviral agents reduces the risk of hepatocellular carcinoma..J Hepatol2018;

[48] Li DK,Fierer DS,Shaikh OS.The short-term incidence of hepatocellular carcinoma is not increased after hepatitis C treatment with direct-acting antivirals: an ERCHIVES study..Hepatology2018;67:2244-53

[49] Waziry R,Grebely J,Law M.Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy: a systematic review, meta-analyses, and meta-regression..J Hepatol2017;67:1204-12

[50] Bagella P,Caruana G.Editorial - non AIDS-defining malignancies: a new epidemic in HIV-infected population for the upcoming decades? European review for medical and pharmacological sciences 2017..Eur Rev Med Pharmacol Sci2017;21:4744-5

[51] Di Benedetto F,Ercolani G,Montalti R.Multicenter Italian experience in liver transplantation for hepatocellular carcinoma in HIV-infected patients..Oncoligst2013;18:592-9 PMCID:PMC3662851

[52] Yang JD,Nguyen MH,Roberts LR.Impact of country of birth on age at the time of diagnosis of hepatocellular carcinoma in the United States..Cancer2017;123:81-9 PMCID:PMC5161593

[53] Yang JD,Cvinar JL,Roberts LR.Diabetes mellitus heightens the risk of hepatocellular carcinoma except in patients with hepatitis C cirrhosis..Am J Gastroenterol2016;111:1573-80 PMCID:PMC6040826

[54] Esfeh JM,Ansari-Gilani K.Sensitivity of ultrasound in detecting hepatocellular carcinoma in obese patients compared to explant pathology as the gold standard..Clin Mol Hepatol2019;26:54-9 PMCID:PMC6940490

[55] Bolondi L.Screening for hepatocellular carcinoma in cirrhosis..J Hepatol2003;39:1076-84

[56] Simmons O,Yokoo T,Yopp A.Predictors of adequate ultrasound quality for hepatocellular carcinoma surveillance in patients with cirrhosis..Aliment Pharmacol Ther2017;45:169-77

[57] Singal A,Waljee A,Higgins P.Meta-analysis: surveillance with ultrasound for early-stage hepatocellular carcinoma in patients with cirrhosis..Aliment Pharmacol Ther2009;30:37-47 PMCID:PMC6871653

[58] Fangazio S,Tran Minh M,Minisini R.Treatment failure after interferon-free treatment of hepatitis C as a clue of a yet undetected hepatocellular carcinoma..J Hepatol2017;

[59] Yen YH,Hung CH,Lu SN.Active hepatocellular carcinoma is an independent risk factor of direct-acting antiviral treatment failure: a retrospective study with prospectively collected data..PLoS One2019;14:e0222605 PMCID:PMC6776434